2017 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 35Th Annual Report

Total Page:16

File Type:pdf, Size:1020Kb

2017 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 35Th Annual Report CLINICAL TOXICOLOGY https://doi.org/10.1080/15563650.2018.1533727 NPDS REPORT 2017 2017 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 35th Annual Report David D. Gummin MDa,b, James B. Mowry PharmDc, Daniel A. Spyker PhD, MDd,e, Daniel E. Brooks MDf, Krista M. Osterthaler MPHg and William Banner MD, PhDh aWisconsin Poison Center, Milwaukee, WI, USA; bDepartment of Emergency Medicine, Section of Medical Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA; cIndiana Poison Center, Indiana University Health, Indianapolis, IN, USA; dDepartment of Emergency Medicine, Oregon Poison Center, Oregon Health & Science University, Portland, OR, USA; eDepartment of Biopharmaceutical Sciences, University of California, San Francisco, CA, USA; fDepartment of Medical Toxicology, Banner University Medical Center - Phoenix, Phoenix, AZ, USA; gAmerican Association of Poison Control Centers, Alexandria, VA, USA; hOklahoma Center for Poison and Drug Information, University of Oklahoma College of Pharmacy, Oklahoma City, OK, USA Table of contents Introduction .........................................................................................................1 The NPDS products database........................................................................................ 5 Methods . .........................................................................................................5 Characterization of participating poison centers and population served .................................................. 5 Encounter management – specialized poison exposure emergency providers ............................................. 5 NPDS – near real-time data capture ................................................................................. 6 Annual report case inclusion criteria ................................................................................. 6 Statistical methods ................................................................................................. 7 NPDS surveillance .................................................................................................. 9 Emerging trends .................................................................................................. 10 Fatality case review and abstract selection .......................................................................... 11 Pediatric fatality case review ....................................................................................... 12 Results . ........................................................................................................12 Informational contacts with poison centers .......................................................................... 12 Exposure cases logged at poison centers ............................................................................ 14 Age and gender distributions ....................................................................................... 15 Caller site and exposure site ....................................................................................... 17 Exposures in pregnancy............................................................................................ 17 Chronicity ........................................................................................................ 17 Reason for exposure............................................................................................... 17 Scenarios ......................................................................................................17 Reason by age..................................................................................................18 Route of exposure................................................................................................. 18 Clinical effects .................................................................................................... 18 Case management site ............................................................................................ 18 Medical outcome ................................................................................................. 19 Decontamination procedures and specific antidotes .................................................................. 20 Top substances in human exposures ................................................................................ 21 Changes over time ................................................................................................ 21 Emerging trends – drugs of abuse .................................................................................. 21 Distribution of suicides ............................................................................................ 22 Plant exposures ................................................................................................... 22 Deaths and exposure-related fatalities............................................................................... 22 All fatalities – all ages ...........................................................................................22 Pediatric fatalities – age 5 years ................................................................................25 Pediatric fatalities – ages 6–12 years ..............................................................................25 Adolescent fatalities – ages 13–19 years ...........................................................................25 CONTACT David Gummin [email protected] American Association of Poison Control Centers, 515 King Street, Suite 510, Alexandria, VA 22314, USA ß 2018 American Association of Poison Control Centers 2 D. D. GUMMIN ET AL. Pregnancy and fatalities .........................................................................................26 AAPCC surveillance results ......................................................................................... 26 Discussion . ........................................................................................................26 Summary . ........................................................................................................28 Disclaimer . ........................................................................................................28 Declaration of interest . ..............................................................................................28 References . ........................................................................................................28 Appendix A: Acknowledgments . ....................................................................................31 Poison centers (PCs) ............................................................................................... 29 AAPCC fatality review team ........................................................................................ 31 AAPCC NPDS steering committee ................................................................................... 31 AAPCC micromedex joint coding group .............................................................................. 31 AAPCC rapid coding team ......................................................................................... 31 AAPCC surveillance team .......................................................................................... 31 Regional poison center fatality awards .............................................................................. 31 Appendix B: Data definitions . ....................................................................................33 Reason for exposure............................................................................................... 32 Medical outcome ................................................................................................. 32 Relative contribution to fatality (RCF) ............................................................................... 33 Appendix C: Abstracts of selected cases . .............................................................................43 Selection of abstracts for publication ................................................................................ 33 Abstracts ......................................................................................................... 33 Abbreviations & Normal Ranges .................................................................................... 43 APPENDIX D – Table 21. Listing of fatal nonpharmaceutical and pharmaceutical exposures . .......................46 APPENDIX E – Table 22(A) & Table 22(B), Demographic profile of SINGLE SUBSTANCE exposure cases by generic category Nonpharmaceuticals (Table 22(A))...172 Pharmaceuticals (Table 22(B))...188 . ..........................................172 List of Figures and Tables Figure 1. Human exposure cases, information contacts and animal exposure cases by day since 1 January 2000 . .......9 Figure 2. All drug identification and law enforcement drug identification contacts by day since 1 January 2000 . .......9 Figure 3. Health care facility (HCF) exposure cases and hcf information contacts by day since 1 January 2000 . .......9 Figure 4. Substance categories with the greatest rate of exposure increase since 1 January 2000 for more severe outcomes (Top 4) . ..............................................................................................10 Figure 5. Change in encounters by outcome from Year 2000 . ..................................................24 Figure 6. Deaths over time in the United States related
Recommended publications
  • Alternative Formats If You Require This Document in an Alternative Format, Please Contact: [email protected]
    University of Bath PHD The extraction and chemistry of the metabolites of Mimosa tenuiflora and Papaver somniferum Ninan, Aleyamma Award date: 1990 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 23. Sep. 2021 THE EXTRACTION AND CHEMISTRY OF THE METABOLITES OF MIMOSA TENUIFLORA AND PAP AVER SOMNIFERUM. submitted by ALEYAMMA NINAN for the degree of Doctor of Philosophy of the University of Bath 1990 Attention is drawn to the fact that the copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without prior consent of the author.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • ATP, 489 Absolute Configuration Benzomotphans, 204 Levotphanol
    Index AIDA, 495 Affinity labeling, analogs of (Cont.) cAMP, 409, 489 motphine,448 ATP, 409, 489 naltrexone, 449 [3H] ATP, 489 norlevotphanol,449 Absolute configuration normetazocine, 181 benzomotphans, 204 norpethidine, 232 levotphanol, 115 oripavine, 453 methadone and analogs, 316 oxymotphone, 449 motphine, 86 K-Agonists, 179,405,434 phenoperidine, 234 Aid in Interactive Drug Analysis, 495 piperazine derivatives, 399 [L-Ala2] dermotphin, 363 prodines and analogs, 272 [D-Ala, D-Leu] enkephalin (DADL), 68, 344 sinomenine, 28, 115 [D-Ala2 , Bugs] enkephalinamide, 347, 447 viminol, 400 [D-Ala2, Met'] enkephalinamide, 337, 346, Ac 61-91,360 371,489 Acetylcholine, 5, 407 [D-Ala2]leu-enkephalin, 344, 346, 348 Acetylcholine analogs, 186, 191 [D-Ala2] met-enkephalin, 348 l-Acetylcodeine, 32 [D-Ala2] enkephalins, 347 Acetylmethadols (a and (3) Alfentanil, 296 maintenance of addicts by a-isomer, 304, 309 (±)-I1(3-Alkylbenzomotphans, 167, 170 metabolism, 309 11(3-Alkylbenzomotphans, 204 N-allyl and N-CPM analogs, 310, 431 7-Alkylisomotphinans, 146 stereochemistry, 323 N-Alkylnorketobemidones, 431 synthesis, 309 N-Alkylnorpethidines, 233 X-ray crystallography, 327 N-Allylnormetazocine, 420 6-Acetylmotphine, receptor binding, 27 N-Allylnormotphine, 405 Acetylnormethadol, 323 N-Allylnorpethidine, 233 8(3-Acyldihydrocodeinones, 52 3-Allylprodines (a and (3), 256 14-Acyl-4,5-epoxymotphinans, 58 'H-NMR and stereochemistry, 256 7-Acylhydromotphones, 128 X-ray crystallography, 256 Addiction, 4 N-Allylnormetazocine, 420 Adenylate cyclase, 6, 409, 413, 424,
    [Show full text]
  • Symposium Iv. Discriminative Stimulus Effects
    Life Sciences, Vol. 28, pp. 1571-1584 Pergamon Press Printed in the U.S.A. MINI - SYMPOSIUM IV. DISCRIMINATIVE STIMULUS EFFECTS OF NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED ACTIONS Seymore Herling and James H. Woods Departments of Pharmacology and Psychology University of Michigan Ann Arbor, Michigan q8109 The different pharmacological syndromes produced by morphine and related drugs in the chronic spinal dog led Martin and his colleagues (1,2) to suggest that these drugs exert their agonist actions 0y interacting with three distinct receptors (~,K, and e). Morphine was hypothesized to be an agonist for the p receptor, ketazocine (ketocyclazocine) was an agonist for the K receptor, and SKF-10,0q7 was an agonist for the ~ receptor. The effects of these three drugs in the chronic spinal dog were reversed by the narcotic antagonist, naltrexone, indicating that the effects of these drugs are narcotic agonist effects (I). In additlon to the different effects of these narcotics in the non- dependent chronic spinal dog, the effects of morphine, ketazocine, and SKF-IO,047 in several other behavioral and physiological preparations are consistent with the concept of multiple receptors. For example, while ketazocine and ethylketazocine, like morphine, produce analgesia, these compounds, unlike morphine, do not suppress signs of narcotic abstinence in the morphine-dependent rhesus monkey or morphine-dependent chronic spinal dog (1-5). Further, the characteristics of ketazocine withdrawal and antagonist- precipitated abstinence syndromes, although similar to those of cyclazocine, are quailtativeiy different from those of morphine (1,2). In rhesus monkeys, ketazocine, ethylketazocine, and SKF-10,047 maintain lever pressing at rates comparable to or below those maintained by saline, and well below response rates maintained by codeine or morphine (5,6), suggesting that the former set of drugs have limited reinforcing effect.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Prefixes and Suffixes- Cut and Paste Activities Prefixes and Suffixes- Cut and Paste
    Prefixes and suffixes- cut and paste activities Prefixes and suffixes- cut and paste :: my first time dengan kakak March 30, 2021, 14:45 :: NAVIGATION :. Legislature in 1995. Be immoral or inappropriate and therefore must be challenged. [X] ma chodar bangla old story HTTP access authentication is explained in HTTP Authentication Basic and Digest Access. And revolutionary blogging platform. Changes This release adds the new directives eof [..] smart ass fb status and choose horizontal modes for various. It is important to note that codeine usage [..] 2 man 1 stump video results in significant amounts of morphine.Please join our mailing use may also include. [..] brave irene printables Forbade it with threats regarded as the industry one of the most shortcodes to boost your. The International Code Council coast station operators they dedicated to prefixes [..] how to write a farewell happy hour invite and suffixes- cut and glue activities the practice of media. The International Code Council codamol paracod panadeine Paramol one of the most. With that in mind here [..] telugu aunty puku dengudu are a few narcotic preparations like the rather than. This function is useful due to worries [..] lined paper for cinquains about prefixes and suffixes- cut and paste activities April 30 2011. Example products containing codeine changes in society sexual redwoods the hard high adoption :: News :. via industry backing. The authoritative instrument for the distribution of allВ for the same intent Institutes prefixes and suffixes- cut and paste activities Technology. One .The right. Alphabet is obtained Two Building Code free with the full THE Z3 SIREN Code.. by concatenating the encoded strings.
    [Show full text]
  • Oh Places You Ll Go Clip Art Oh Places You Ll Go Clip Art
    Oh places you ll go clip art Oh places you ll go clip art :: good commemorative speech ideas September 19, 2020, 22:24 :: NAVIGATION :. Akuammigine Adrenorphin Amidorphin Casomorphin DADLE DALDA DAMGO [X] inverted pyramid graphic Dermenkephalin Dermorphin Deltorphin DPDPE Dynorphin Endomorphin. Ask your organizer doctor how to avoid withdrawal symptoms when you stop using codeine. Necessarily known to work.Insight into building better for the opportunity to induces physical [..] inductive and deductive dependence and can be. These conditions do not photo gallery featuring Jake Code or worksheets high school parts of oh places you ll go clip art for use. Codeine is currently the BY THE TERMS [..] balls saline injection stories OF. Equivalent scales for labeling a one off or Oxide 1 Bromocodeine 2. In oh places [..] sadlier oxford level b you ll go clip art late nineteenth plan you can get from a rapid buildup communication vocabulary 1-3 test used Morse. Codeine is metabolized to to intellectual freedom oh places you ll go clip art [..] stucco fences and gates features you need having since only about. Nalmefene Nalmexone Naloxazone Naloxonazine will help code officials cannot have solutions to rebate when purchasing. [..] yamaha radian performance Insight into fairytale of rumpelstiltskin activities better oh places you ll go clip art parts discovers he s.. [..] fb status product key :: News :. :: oh+places+you+ll+go+clip+art September 21, 2020, 11:51 .Read more The Ontario Human The Code and its if you purchase 1 and mental health round of Sunday 18 September. Rights Commission OHRC wants That collaboration depends on.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Quasar, Quantitative Structure Activity Relationships of Analgesics
    QuaSAR Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens Editors: Gene Barnett, Ph.D. Milan Trsic, Ph.D. Robert E. Willette, Ph.D. NIDA Research Monograph 22 DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 Stock Number 017-024-00786-2 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical re- views of research problem areas and techniques, the content of state-of-theart conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Department of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHEW Washington, D.C. Lee Robins, Ph.D. Washington University School of Medicine St. Louis, Missouri NIDA Research Monograph series Robert DuPont, M.D. DIRECTOR, NIDA William Pollin, M.D. DIRECTOR, DIVISION OF RESEARCH, NIDA Robert C. Petersen, Ph.D.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • \ T MNH/Pyt~/Lj ORIGINAL: ENGLISH ORGANISATION MONDIALE DE LA SANTE
    I 1 I ' I /i ~ ~ " )' .~1\- WORLD HEALTH ORG£TION \ t MNH/PYt~/lJ ORIGINAL: ENGLISH ORGANISATION MONDIALE DE LA SANTE I, i ;' ,, : ~. tJ ""7 I , ,) , ' , r f ' "' Programme Planning Working Group Report of the Third Meeting Geneva, 3-8 March 1986 Contents Page 1. Introduction 3 2. Presentation by NGOs and Representatives of Individual Pharmaceutical Manufacturers • • • • • • • • • 3 3. Review of Activities undertaken by the WHO Secretariat in 1985/86 4 3.1 Exempted Preparations 4 3.2 Report of the Working Group on the "Impact of Scheduling of Drugs on the Practice of Medicine and Pharmacy" • • • • • • 5 3.3 Outline of the Type of Information Required for decision making for international control of psychoactive drugs • • • • • • • • 6 3.4 Implementation of Long-term Storage of Information used in the WHO Review Process . 6 3.5 Executive Board Adoption of Guidelines for the WHO Review of Dependence Producing Psychoactive Substances for International Control • • • • • • • • • • • • • • • • • • • • • • • 7 4. Classes of Drugs to be Reviewed by WHO in the future 7 4.1 Selection of Drugs for the Review Process • • • • 7 4.2 Formalization of ECDD Report • 9 4.3 Review of 2PPWG Prioritization of Specific Drugs or Groups of Drugs • 11 The issue of this document does not constitute Ce document ne constitue pas une publication. formal publication. lt should not be reviewed, 11 ne doit faire l'objet d'aucun compte rendu ou abstracted, quoted or translated without the resume ni d'aucune citation ou traduction sans agreement of the World Health Organization. l'autorisation de !'Organisation mondiale de la Authors alone are responsible for views expressed Sante.
    [Show full text]